Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc. operates in various business sectors.
Aldeyra Therapeutics Inc. (137) - Net Assets
Latest net assets as of June 2024: €98.31 Million EUR
Based on the latest financial reports, Aldeyra Therapeutics Inc. (137) has net assets worth €98.31 Million EUR as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€126.04 Million) and total liabilities (€27.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €98.31 Million |
| % of Total Assets | 78.0% |
| Annual Growth Rate | 6.7% |
| 5-Year Change | 149.15% |
| 10-Year Change | N/A |
| Growth Volatility | 107.46 |
Aldeyra Therapeutics Inc. - Net Assets Trend (2018–2023)
This chart illustrates how Aldeyra Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aldeyra Therapeutics Inc. (2018–2023)
The table below shows the annual net assets of Aldeyra Therapeutics Inc. from 2018 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €119.80 Million | -20.67% |
| 2022-12-31 | €151.01 Million | -26.60% |
| 2021-12-31 | €205.74 Million | +245.72% |
| 2020-12-31 | €59.51 Million | +23.76% |
| 2019-12-31 | €48.08 Million | -44.49% |
| 2018-12-31 | €86.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aldeyra Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25572398000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €514.05 Million | 429.11% |
| Total Equity | €119.80 Million | 100.00% |
Aldeyra Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Aldeyra Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bowen Acquisition Corp Rights
NASDAQ:BOWNR
|
$44.98K |
|
OKASAN SEC GRP
MU:OKN
|
$45.01K |
|
CARRARO
NSE:CARRARO
|
$45.11K |
|
VCI Global Limited Ordinary Share
NASDAQ:VCIG
|
$45.12K |
|
PFERDEWETTEN AG
STU:EMH1
|
$44.95K |
|
INZI Controls Co. Ltd.
KQ:023800
|
$44.95K |
|
TANZANIA CIGARETTE CO. LTD
DSE:TCC
|
$44.93K |
|
FS Credit Opportunities Corp.
NYSE:FSCO
|
$44.91K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aldeyra Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 151,008,029 to 119,795,030, a change of -31,212,999 (-20.7%).
- Net loss of 37,542,510 reduced equity.
- Other factors increased equity by 6,329,511.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-37.54 Million | -31.34% |
| Other Changes | €6.33 Million | +5.28% |
| Total Change | €- | -20.67% |
Book Value vs Market Value Analysis
This analysis compares Aldeyra Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.18x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.34x to 2.18x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €3.30 | €4.42 | x |
| 2019-12-31 | €1.68 | €4.42 | x |
| 2020-12-31 | €1.54 | €4.42 | x |
| 2021-12-31 | €3.54 | €4.42 | x |
| 2022-12-31 | €2.58 | €4.42 | x |
| 2023-12-31 | €2.02 | €4.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aldeyra Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.24x
- Recent ROE (-31.34%) is above the historical average (-51.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -44.90% | 0.00% | 0.00x | 1.10x | €-47.56 Million |
| 2019 | -102.46% | 0.00% | 0.00x | 1.57x | €-54.07 Million |
| 2020 | -63.11% | 0.00% | 0.00x | 1.40x | €-43.50 Million |
| 2021 | -28.08% | 0.00% | 0.00x | 1.13x | €-78.35 Million |
| 2022 | -41.07% | 0.00% | 0.00x | 1.20x | €-77.13 Million |
| 2023 | -31.34% | 0.00% | 0.00x | 1.24x | €-49.52 Million |
Industry Comparison
This section compares Aldeyra Therapeutics Inc.'s net assets metrics with peer companies in the same industry.
No peer company data available for comparison.